From July 1 to September 30, 2026, Health Canada approved 16 new drug submissions (14 pharmaceuticals, 2 biologics) and 540 new medical devices, including 27 Class IV medical devices, which present the greatest potential risk. During this period, Health Canada also approved 30 generic drugs and 3 biosimilar drugs.